The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
💡 한 문장 핵심
양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
5/5 보강
TL;DR
The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.
📑 코퍼스 인용 관계
· 인용됨 41
📑 인용한 논문 (6) ▾
- SRD5A2 and emerging therapies in androgen-driven disorders. Nature reviews. Urology · 2026
- Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics an… BJU international · 2026
- Temperature-dependent phase transition microemulsions for enhanced transdermal delivery of… Scientific reports · 2025
- Comment on Current Investigations into the Postfinasteride Syndrome. International journal of trichology · 2024
- Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalaf… Journal of personalized medicine · 2023
- Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psy… Skin appendage disorders · 2019
연도별 인용 (2012–2026) · 합계 274
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Urinary Bladder and Prostate Research
Sexual function and dysfunction studies
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
양성 전립선비대증(BPH, benign prostatic hyperplasia) 환자에서 5α-환원효소(5 alpha-reductase) 억제제인 피나스테리드(finasteride)가 테스토스테론의 디하이드로테스토스테론(DHT) 전환을 차단하여 전립선 크기 및 배뇨장애 증상을 개선하는지 평가하고자 하였다.
【방법】
이중맹검 연구로, BPH 남성 895명을 대상으로 피나스테리드 1mg, 5mg, 위약을 1일 1회 12개월간 투여하고 배뇨 증상 점수, 요속, 전립선 용적, 혈중 DHT 및 전립선특이항원(PSA) 농도를 주기적으로 측정하였다.
【주요 결과】
5mg군은 위약 대비 총 배뇨증상 점수 유의한 감소(P<0.001), 최대요속 1.6 mL/sec(22%) 증가, 전립선 용적 19% 감소를 보였다. 1mg군은 증상 점수 감소는 유의하지 않았으나 요속·용적 개선은 유사하였다. 다만 피나스테리드군에서 성욕 감퇴, 발기부전, 사정장애 빈도가 위약군보다 높게 나타났다.
【임상적 시사점 (성형외과 의사 관점)】
피나스테리드는 동일한 5α-환원효소 억제 기전으로 남성형 탈모(androgenetic alopecia) 치료에 1mg 용량(프로페시아)으로 광범위하게 사용되므로, 모발이식·탈모 상담 시 본 연구가 보여준 성기능 관련 이상반응(libido 저하, 발기부전, 사정장애)에 대한 사전 고지가 필수적이다. 또한 PSA 수치를 낮추는 약리작용을 고려해 중장년 남성 환자 상담 시 전립선암 선별검사 결과 해석에 영향을 줄 수 있음을 안내해야 한다.
[BACKGROUND] Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5 alpha-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction.
[METHODS] In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period.
[RESULTS] As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P less than 0.001), an increase of 1.6 ml per second (22 percent, P less than 0.001) in the maximal urinary-flow rate, and a 19 percent decrease in prostatic volume (P less than 0.001). The men treated with 1 mg of finasteride per day did not have a significant decrease in total urinary-symptom scores, but had an increase of 1.4 ml per second (23 percent) in the maximal urinary-flow rate, and an 18 percent decrease in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups.
[CONCLUSIONS] The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.
[METHODS] In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period.
[RESULTS] As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P less than 0.001), an increase of 1.6 ml per second (22 percent, P less than 0.001) in the maximal urinary-flow rate, and a 19 percent decrease in prostatic volume (P less than 0.001). The men treated with 1 mg of finasteride per day did not have a significant decrease in total urinary-symptom scores, but had an increase of 1.4 ml per second (23 percent) in the maximal urinary-flow rate, and an 18 percent decrease in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups.
[CONCLUSIONS] The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.
【연구 목적】 양성 전립선비대증(BPH, benign prostatic hyperplasia) 환자에서 5α-환원효소(5 alpha-reductase) 억제제인 피나스테리드(finasteride)가 테스토스테론의 디하이드로테스토스테론(DHT) 전환을 차단하여 전립선 크기 및 배뇨장애 증상을 개선하는지 평가하고자 하였다.
APA 7
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., & Tenover, J. S. (1992). The effect of finasteride in men with benign prostatic hyperplasia. The finasteride study group.. The New England journal of medicine, 327(17), 1185-91. https://doi.org/10.1056/NEJM199210223271701
Vancouver
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. jour. medi.. 1992;327(17):1185-91. doi:10.1056/NEJM199210223271701
AMA 11
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. jour. medi.. 1992;327(17):1185-91. doi:10.1056/NEJM199210223271701
Chicago
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., and Tenover, J. S.. 1992. "The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group." The New England journal of medicine 327 (17): 1185-91. https://doi.org/10.1056/NEJM199210223271701
MLA 9
Gormley, G. J., et al. "The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group." The New England journal of medicine, vol. 327, no. 17, 1992, pp. 1185-91. doi:10.1056/NEJM199210223271701.
PMID
1383816 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 20
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic …
- Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.
- Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year ran…
- Clinical pharmacokinetics and pharmacodynamics of finasteride.
- Development of finasteride polymer microspheres for systemic application in androgenic alopecia.
- The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
- Finasteride for benign prostatic hyperplasia.
- Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
- Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a seri…
- Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic I…
- Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of random…
- A Comment on the Post-Finasteride Syndrome.
- Finasteride-its impact on sexual function and prostate cancer.
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
- Comparison of clinical trials with finasteride and dutasteride.
- Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
- Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Tri…
- The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, …
- Connexin 43 expression in the testes during postnatal development of finasteride-treated male rat of…
- Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fib…
같은 제1저자의 인용 많은 논문 (5)
- Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
- The effect of finasteride in men with benign prostatic hyperplasia. 1992.
- Finasteride: a clinical review.
- The potential application of finasteride for chemoprevention of prostate cancer.
- Evaluation of men on finasteride.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.